Alunbrig and Amylase increased - a phase IV clinical study of FDA data

Summary:

Amylase increased is reported as a side effect among people who take Alunbrig (brigatinib), especially for people who are male, 60+ old, have been taking the drug for < 1 month also take Magnesium Oxide, and have Lung neoplasm malignant.

The phase IV clinical study analyzes which people have Amylase increased when taking Alunbrig. It is created by eHealthMe based on reports of 1,224 people who have side effects when taking Alunbrig from the FDA, and is updated regularly.

What is Alunbrig?

Alunbrig has active ingredients of brigatinib. eHealthMe is studying from 1,224 Alunbrig users. Check the latest studies of Alunbrig.

What is Amylase increased?

Amylase increased is found to be associated with 402 drugs and 734 conditions by eHealthMe. Check the latest studies of Amylase increased.

On Aug, 01, 2026

1,224 people reported to have side effects when taking Alunbrig.
Among them, 46 people (3.76%) have Amylase increased.

Among these 46 people:

How long have people been on Alunbrig when they have Amylase increased? *

What is the gender of people who have Amylase increased when taking Alunbrig? *

female: 50 %
male: 50 %

What is the age of people who have Amylase increased when taking Alunbrig? *

What are other drugs people take besides Alunbrig? *

Spironolactone: 3 people, 6.52%
Olopatadine Hydrochloride: 3 people, 6.52%
Magnesium Oxide: 3 people, 6.52%
Zolpidem Tartrate: 1 person, 2.17%
Sitagliptin Phosphate: 1 person, 2.17%
Nifedipine: 1 person, 2.17%
Miglitol: 1 person, 2.17%
Lyrica: 1 person, 2.17%
Lorazepam: 1 person, 2.17%
Lansoprazole: 1 person, 2.17%

What are other side effects people have besides Amylase increased? *

Blood Creatine Phosphokinase Increased: 21 people, 45.65%
Lipase Increased: 12 people, 26.09%
High Blood Pressure: 10 people, 21.74%
Disease Progression: 8 people, 17.39%
Diarrhea: 7 people, 15.22%
Metastases To Central Nervous System (cancer spreads to central nervous system): 6 people, 13.04%
Lung Neoplasm Malignant (cancer tumour of lung): 5 people, 10.87%
Nausea (feeling of having an urge to vomit): 5 people, 10.87%
Aspartate Aminotransferase Increased: 5 people, 10.87%
Lung Cancer - Non-Small Cell (lung cancer): 4 people, 8.70%

What are the existing conditions these people have? *

Lung Neoplasm Malignant (cancer tumour of lung): 17 people, 36.96%
Lung Cancer - Non-Small Cell (lung cancer): 15 people, 32.61%
Lung Adenocarcinoma (a form of non-small cell lung cancer): 6 people, 13.04%
Lung Adenocarcinoma Stage Iv (the cancer has spread to other organs of the body, such as the other lung, brain, or liver): 2 people, 4.35%
Lung Adenocarcinoma Stage Iii (the cancer has spread to nearby tissue or too far away lymph nodes): 2 people, 4.35%
Lung Carcinoma Cell Type Unspecified Recurrent (lung cancer reoccurrence): 1 person, 2.17%
Enterocolitis (inflammation of the digestive tract, involving enteritis of the small intestine and colitis of the colon): 1 person, 2.17%
Diabetes: 1 person, 2.17%

* Approximation only. Some reports may have incomplete information.

Do you take Alunbrig and have Amylase increased?

- Check whether Amylase increased is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Alunbrig:

Alunbrig (1,224 reports)

Browse all side effects of Alunbrig:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Amylase increased:

Amylase increased (402 drugs)

Browse all the conditions that are associated with Amylase increased:

Amylase increased (734 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on brigatinib (the active ingredients of Alunbrig) and Alunbrig (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.